Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study ; volume:14 ; number:2 ; year:2021 ; pages:706-715 ; extent:10
Case reports in oncology ; 14, Heft 2 (2021), 706-715 (gesamt 10)
- Creator
- DOI
-
10.1159/000515416
- URN
-
urn:nbn:de:101:1-2021090900431306846394
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Anžič, Nina
- Krasniqi, Fatime
- Eberhardt, Anna-Lena
- Tzankov, Alexandar
- Haslbauer, Jasmin Dionne
Other Objects (12)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
Characterisation of fused in sarcoma deficient C57BL/6 mice
Pembrolizumab
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
Ipilimumab induced digital vasculitis
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Pembrolizumab for all
A 37-Year-Old Man with Myofibroblast Sarcoma Combined with Pleural Maculopathy: Case Report
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
Characterisation of fused in sarcoma deficient C57BL/6 mice
Pembrolizumab
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
Ipilimumab induced digital vasculitis
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Pembrolizumab for all
A 37-Year-Old Man with Myofibroblast Sarcoma Combined with Pleural Maculopathy: Case Report
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
Characterisation of fused in sarcoma deficient C57BL/6 mice
Pembrolizumab
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
Ipilimumab induced digital vasculitis
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Pembrolizumab for all